Title: 2016 ACVIM Forum Research Abstract Program Document date: 2016_5_31
ID: 2y1y8jpx_554
Snippet: These findings suggest that FGF-23 concentrations rise in canine CKD before other traditional markers of RHPT do. Consequently, FGF-23 concentrations should be considered as an early indicator of disease progression, RHPT, and potential target for therapeutic intervention. Erythropoiesis-stimulating agents are currently recommended for veterinary patients with anemia secondary to chronic kidney disease (CKD). Darbepoetin alfa (darbepoetin) has re.....
Document: These findings suggest that FGF-23 concentrations rise in canine CKD before other traditional markers of RHPT do. Consequently, FGF-23 concentrations should be considered as an early indicator of disease progression, RHPT, and potential target for therapeutic intervention. Erythropoiesis-stimulating agents are currently recommended for veterinary patients with anemia secondary to chronic kidney disease (CKD). Darbepoetin alfa (darbepoetin) has replaced epoetin due to a three-fold longer half-life allowing for less frequent dosing. Also, darbepoetin is perceived to be less likely to elicit formation of anti-erythropoietin antibodies resulting in pure red cell aplasia (PRCA). A previous study examined the efficacy of darbepoetin in cats with CKD; 14 of 25 cats responded, with adverse events observed in 12 cats, including two with possible PRCA. This retrospective study evaluated response to darbepoetin therapy, protocols for administration, and potential adverse events in dogs with CKD.
Search related documents:
Co phrase search for related documents- disease progression and early indicator: 1, 2, 3
- disease progression and kidney disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- disease progression and possible PRCA: 1
- disease progression and potential target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- disease progression and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- disease progression and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- disease progression and therapeutic intervention: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- disease progression and therapeutic intervention potential target: 1
- disease progression and veterinary patient: 1
- early indicator and kidney disease: 1, 2, 3
- early indicator and previous study: 1
- early indicator and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- frequent dosing and retrospective study: 1
- previous study and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
- previous study and therapeutic intervention: 1, 2
- retrospective study and therapeutic intervention: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Co phrase search for related documents, hyperlinks ordered by date